SAN FRANCISCO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing ...
Nurix Therapeutics (NRIX) leads in targeted protein modulation with its DELigase platform, developing BTK degraders like ...
Learn about Nurix Therapeutics (NRIX) focusing on protein degradation in cancer treatment, with promising early-stage data ...
Zacks.com on MSN2d
Strength Seen in SpringWorks Therapeutics (SWTX): Can Its 6.0% Jump Turn into More Strength?SpringWorks Therapeutics (SWTX) witnessed a jump in share price last session on above-average trading volume. The latest ...
(MENAFN- GlobeNewsWire - Nasdaq) SAN FRANCISCO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein ...
2d
Generation Bio (GBIO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Gil Blum from ...
Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company focused on developing targeted small molecule therapies, has been garnering significant investor attention, with... ByInvesting ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Investing.com - Nurix (NASDAQ: NRIX) reported third quarter EPS of $-0.68, $0.16 better than the analyst estimate of $-0.84. Revenue for the quarter came in at $18.47M versus the ...
NX-5948 has received fast track designation for adults with relapsed or refractory Waldenström macroglobulinemia who received ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback